Talon Therapeutics Inc (fka TLON)

[goodwill4all]

Here is what went wrong with Allos - interesting that Allos had an orphan drug with limited patient pop. like TLON

The company's business strategy may have been a major factor. While Folotyn proved to be a relatively successful drug, Allos wasn't following a business plan that would allow for the company to be markedly successful, said Michael Becker, a partner at boutique cancer consulting firm MD Becker Partners.

Allos' business model appeared to replicate that of a larger company, such as Amgen Inc., which has drugs with high volume sales that target large patient populations. However, Allos' Folotyn was a niche drug -- technically designated an orphan drug by the FDA. That means it targets a patient population of fewer than 200,000, which likely limited sales, Becker said.